0GRZ Stock Chart & Stats
kr176.60
kr1.82(1.10%)
At close: 4:00 PM EDT
kr176.60
kr1.82(1.10%)
Day’s Range― - ―
52-Week Rangekr161.00 - kr266.50
Previous CloseN/A
Volume13.70K
Average Volume (3M)10.04K
Market Cap
kr6.07B
Enterprise Valuekr7.68K
Total Cash (Recent Filing)kr213.10M
Total Debt (Recent Filing)kr359.20M
Price to Earnings (P/E)28.5
Beta0.79
Next Earnings
Nov 03, 2026EPS Estimate
2.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.21
Shares Outstanding30,799,536
10 Day Avg. Volume6,041
30 Day Avg. Volume10,037
Financial Highlights & Ratios
PEG Ratio2.87
Price to Book (P/B)7.93
Price to Sales (P/S)5.81
P/FCF Ratio21.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.63
Revenue Forecast (FY)kr1.41B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash GenerationHigh gross and operating margins, combined with robust free cash flow, indicate a scalable software model with strong cash conversion. This provides resources for product development, global expansion and resilience through periods of uneven license demand.
Recurring Support Revenue Adds StabilityMaintenance and support revenue creates a recurring base alongside license sales, helping fund operations and reduce dependence on new installations. Its growing mix should improve revenue visibility as the installed customer base expands.
Large Backlog And Broad Clinical FootprintStrong order intake and a sizable backlog support forward revenue visibility, while broad international adoption reduces reliance on one market. The customer footprint can also reinforce RaySearch's ecosystem position in oncology software.
Bears Say
Weak Recent License Growth And Execution RiskThe decline in license revenue and profitability shows that deal timing and execution remain material risks. Management requires double-digit sales growth in the second half to reach its 2026 margin target, leaving limited room for further delays.
U.S. Procurement And China Market-access HeadwindsHealthcare procurement cycles and reimbursement constraints can prolong sales conversion in the U.S., while regulation and local-vendor preferences restrict Chinese access. These are structural market-entry frictions that may limit geographic growth.
Limited Subscription Adoption Increases Revenue VolatilityReliance on upfront CapEx purchases makes revenue more sensitive to hospital budgets, procurement timing and project phasing than a subscription-led model. Limited SaaS adoption therefore constrains near-term smoothing of license volatility.
RaySearch Laboratories AB News
0GRZ FAQ
What was RaySearch Laboratories AB Class B’s price range in the past 12 months?
RaySearch Laboratories AB Class B lowest share price was kr161.00 and its highest was kr266.50 in the past 12 months.
What is RaySearch Laboratories AB Class B’s market cap?
RaySearch Laboratories AB Class B’s market cap is kr6.07B.
When is RaySearch Laboratories AB Class B’s upcoming earnings report date?
RaySearch Laboratories AB Class B’s upcoming earnings report date is Nov 03, 2026 which is in 58 days.
How were RaySearch Laboratories AB Class B’s earnings last quarter?
RaySearch Laboratories AB Class B released its earnings results on Aug 13, 2026. The company reported kr0.57 earnings per share for the quarter, missing the consensus estimate of kr1.185 by -kr0.615.
Is RaySearch Laboratories AB Class B overvalued?
According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued.
Does RaySearch Laboratories AB Class B pay dividends?
RaySearch Laboratories AB Class B does not currently pay dividends.
What is RaySearch Laboratories AB Class B’s EPS estimate?
RaySearch Laboratories AB Class B’s EPS estimate is 2.55.
How many shares outstanding does RaySearch Laboratories AB Class B have?
RaySearch Laboratories AB Class B has 30,799,536 shares outstanding.
What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?
RaySearch Laboratories AB Class B reported an EPS of kr0.57 in its last earnings report, missing expectations of kr1.185. Following the earnings report the stock price went down -0.341%.
Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?
Currently, no hedge funds are holding shares in GB:0GRZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaySearch Laboratories AB Class B
RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vast range of clinical activities. These capabilities include automated planning, adaptive therapy, multi-criteria optimization, rapid and accurate dose calculations, OAR dose reduction, robustness modeling, machine learning integration, and support for advanced radiation modalities such as VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic treatments, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also offers RayPlan, another treatment planning system specifically designed for various radiation therapy methods including 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy. For managing oncology workflows, RayCare serves as a dedicated information system. Additionally, RaySearch provides RayCommand, a flexible treatment control system compatible with diverse hardware and designed to manage advanced functionalities of treatment machines and software. To leverage patient data, its cloud-based oncology analytics system, RayIntelligence, converts raw information into valuable insights. RaySearch Laboratories AB (publ) further provides training courses for its products and is headquartered in Stockholm, Sweden.
0GRZ Company Deck
0GRZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reported a clearly disappointing Q2 with meaningful declines in license and hardware sales (license -18%, hardware -38%, net sales -11%) and a compressed EBIT margin (10%). However, several positive indicators offset the weakness: order intake grew 23%, backlog remains robust at SEK 1.691 billion (SEK 670 million expected to convert within 12 months), LTM organic growth was 9% with a 22% LTM EBIT margin, notable strategic wins (Dana-Farber and other U.S. orders recovered in early Q3), clinical milestones (online adaptive treatments on TrueBeam), product releases and strengthened proton expertise, improved cash flow (Q2 free cash flow SEK 50 million) and active share repurchases. Management believes a strong H2 can restore the year’s financial trajectory but execution risk remains. Overall, the positive backlog, early Q3 order recoveries and recurring revenue stability balance the quarter’s operational weaknesses and timing risks.View all GB:0GRZ earnings summariesTechnical Analysis
Paxman AB
―
C-Rad AB Class B
―
Sectra AB Class B
―
Mentice AB
―
Surgical Science Sweden AB
―